Chemotherapy Plus Targeted Therapies Shows Improved Survival In Advance-stage Lung Cancer Patients
Tuesday, November 25, 2008 - 13:36
in Health & Medicine
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.
Read the whole article on Science Daily
More from Science Daily
Related
- Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patientsThu, 13 Nov 2008, 10:51:01 EST
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- Tissue analyses indicate survival benefits for some lung cancer patientsThu, 13 Nov 2008, 10:51:06 EST
- Proton therapy may reduce serious side effect of lung cancer treatmentThu, 13 Nov 2008, 10:51:08 EST
- Gender is key factor in determining overall survival of lung cancer patientsThu, 13 Nov 2008, 10:51:11 EST